Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. [electronic resource]
Producer: 20120604Description: 3532-41 p. digitalISSN:- 1550-6606
- Alemtuzumab
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antibody-Dependent Cell Cytotoxicity
- Antigens, CD20 -- immunology
- Antigens, Neoplasm -- immunology
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- B-Lymphocyte Subsets -- drug effects
- Cell Line, Tumor -- drug effects
- Combined Modality Therapy
- Complement Activation
- Complement C3b -- analysis
- Complement C4b -- analysis
- Complement System Proteins -- immunology
- Cyclophosphamide -- administration & dosage
- Cytotoxicity, Immunologic
- Humans
- Immunotherapy
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Lymphocyte Count
- Opsonin Proteins -- immunology
- Rituximab
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.